Next, we tested CSF TREM2 levels in subjects clinically diagnosed with MCI but showing no CSF biomarker profile of AD pathology (MCI‐noAD), that is, biomarkers do not indicate a high likelihood that the MCI syndrome is due to AD (Albert et al, 2011). This evidence concerns the gene TREM2 and Alzheimer disease.